PI(A1/A2) polymorphism of platelet glycoprotein IIIa and risks of myocardial infarction, stroke, and venous thrombosis

Lancet

Volumn 349, Issue 9049, 1997, Pages 385-388

  Ridker, Paul M ^a   Hennekens, Charles H ^a,b,d   Schmitz, Christian ^a   Stampfer, Meir J ^a,d   Lindpaintner, Klaus ^a,c,d  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b Dept of Ambulatory Care and Prev ^*  (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; GLYCOPROTEIN IIIA; DNA; FIBRINOGEN RECEPTOR;

ADULT; AGED; ALLELE; ARTICLE; BLOOD SAMPLING; COHORT ANALYSIS; DNA DETERMINATION; FAMILY HISTORY; GENETIC POLYMORPHISM; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; NORMAL HUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; SMOKING; STROKE; THROMBOCYTE; VEIN THROMBOSIS; BODY MASS; CEREBROVASCULAR DISEASE; GENETICS; MIDDLE AGED; POINT MUTATION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; THROMBOEMBOLISM; UNITED STATES;

ADULT; AGED; AGED, 80 AND OVER; ALLELES; ASPIRIN; BODY MASS INDEX; CEREBROVASCULAR DISORDERS; COHORT STUDIES; DNA; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; POINT MUTATION; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; PROSPECTIVE STUDIES; RISK FACTORS; SMOKING; THROMBOEMBOLISM; UNITED STATES;

EID: 0030614495     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(97)80010-4     Document Type: Article

References (17)

1. Lefkovits J, Plow EF, Topol EJ. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Engl J Med 1995; 332: 1553-59.
2. Coller BS. Blockade of platelet GPIIb/IIIa receptors as an antithrombotic strategy. Circulation 1995; 92: 2373-80.
3. Theroux P, Kouz S, Knudtson ML. A randomized double-blind controlled trial with the non-peptidic platelet GPIIb/IIIa antagonist RO 44-9883 in unstable angina. Circulation 1994, 90:1-232 (abstr).
4. Simoons ML, De Boer MJ, van den Brand MJ, et al. Randomized trial of a GPIIb/IIIa platelet receptor blocker in refractory unstable angina. Circulation 1994; 89: 596-603.
5. Schulman SP, Goldschmidt-Clermont PJ, Navetta FI, et al. Integrelin in unstable angina: a double-blind randomized trial. Circulation 1993; 88: 1-608 (abstr).
6. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994; 330: 956-61.
7. Topol EJ, Califf RM, Weisman HF, et al. Randomized trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: result at six months. Lancet 1994; 343: 881-86.
8. Tcheng JE, Harrington RA, Kottke-Marchant K, et al. Multi-center, randomized, double-blind, placebo-controlled trial of the platelet integrin glycoprotein IIb-IIIa blocker integrelin in elective coronary intervention. Circulation 1995; 91: 2151-57.
9. Kleiman NS, Ohman EM, Califf RM, et al. Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab following thrombolytic therapy: results of the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 8 pilot study. J Am Coll Cardiol 1993; 22: 381-89.
10. Ohman EM, Kleiman NS, Talley JD, et al. Simultaneous platelet glycoprotein IIb/IIIa integrin blockade with accelerated tissue plasminogen activator in acute myocardial infarction. Circulation 1994; 90: 1-564 (abstr)
11. 33 amino acid polymorphism in membrane glycoprotein IIIa, and are distinguishable by DNA typing. J Clin Invest 1989; 83: 1778-81.
12. Jin Y, Dietz HC, Nurden A, Bray PF. Single-strand conformation polymorphism analysis is a rapid and effective method for the identification of mutations and polymorphisms in the gene for glycoprotein IIIa. Blood 1993; 82: 2281-88.
13. Weiss EJ, Bray PF, Tayback M, et al. A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis. N Engl J Med 1996; 334: 1090-94.
14. Simsek S, Faber NM, Bleeker PM, et al. Determination of human platelet antigen frequencies in the Dutch population by immunophenotyping and DNA (allele-specific restriction enzyme) analysis. Blood 1993; 81: 835-40.
15. Steering Committee for the Physicians' Health Study Research Group. Final report of the aspirin component of the ongoing Physicians' Health Study. N Engl J Med 1989; 321: 129-35.
16. Ridker PM, Hennekens CH, Lindpaintner K, Stampfer MJ, Eisenberg PR, Milerich JP. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med 1995; 332: 912-17.
17. von dem Borne AEG, Decary F. Nomenclature of platelet-specific antigens. Transfusion 1990; 30: 477.